
-
Alcaraz out of Shanghai after winning eighth title of season
-
Nche starts for South Africa as they eye Rugby Championship title against Argentina
-
AI tool helps researchers treat child epilepsy
-
US stocks fall as government shutdown looms
-
Brigitte Bardot slams Saint-Tropez after decades in jet-set port
-
Pentagon chief tells US military leaders to fix 'decades of decay'
-
Spotify founder Daniel Ek to give up CEO role
-
Barca star Yamal must 'work hard' to reach top level, says Flick
-
EU green lights Prada's bid for Versace
-
New youth-led protests in Madagascar despite government's dismissal
-
Sinner to face teenager Tien in Beijing final as Gauff battles on
-
Typhoon Bualoi inflicts death, lasting floods on Vietnam
-
Gold hits record, dollar drops as US shutdown looms
-
Hamas reviewing Trump's Gaza plan
-
Alcaraz beats Fritz in Tokyo for eighth title of season
-
Lingering Typhoon Bualoi inflicts death, flooding on Vietnam
-
Vietnam jails former officials over gold bar graft: state media
-
German far-right MP's ex aide jailed for spying for China
-
Who will take 30,000 asylum seekers? EU solidarity faces big test
-
PSG's Kvaratskhelia to miss Barcelona Champions League trip
-
Endometriosis test backed by French government under scrutiny
-
Madagascar protesters undeterred despite sacking of government
-
Saliba signs new long-term deal at Arsenal
-
Sinner powers into Beijing final as Gauff survives Bencic test
-
Madagascar protesters mobilise despite firing of government
-
Gauff calls for shorter tennis seasons as 'impossible' to play more
-
Hamas yet to respond on Trump's Gaza plan
-
Long-lasting Typhoon Bualoi devastates Vietnam, killing 19
-
Dozens missing, three dead in Indonesia school collapse
-
India hot favourites for home Tests against struggling West Indies
-
Taliban internet cut sparks Afghanistan telecoms blackout
-
Gold hits record, stocks mixed as US shutdown looms
-
San Siro on course for demolition after sale to Inter and AC Milan approved
-
Trial opens over Bangkok murder of French-Cambodian ex-MP
-
Gauff survives tense Bencic test to reach Beijing quarter-finals
-
US careens toward government shutdown as both parties dig in
-
Wolf attack in Greece prompts calls for hunting rights
-
Trump to address rare mass meeting of US military leaders
-
Iranian director Jafar Panahi defies censors again with new film
-
Taliban impose communications blackout across Afghanistan
-
Barca's Yamal eyes up PSG after Ballon d'Or miss
-
PSG facing injury crisis as Barcelona present first big test
-
British bettor Bloom's football empire blossoming with Belgian club USG
-
US tariffs on lumber imports set for October 14
-
Australia lose Maxwell for New Zealand T20s after freak net blow
-
India plans mega-dam to counter China water fears
-
Colombia manufactures its first rifles to replace Israeli weapons
-
Stocks rise, gold hits record as rate cuts and shutdown loom
-
Dolphins star Hill suffers gruesome injury in Jets clash
-
Paralympics' vote to lift Russian suspension 'bold step' as conflict rages: ex-IOC executive

CBD Life Sciences Inc. (CBDL) Secures Landmark Agreement with Bronx Powerhouse Dispensary Smoking Scholars
With New York dispensaries projected to surpass $4.4 billion in annual sales by 2027, CBDL secures a transformative partnership poised to generate multi-million-dollar revenues and accelerate nationwide expansion.
With New York dispensaries projected to surpass $4.4 billion in annual sales by 2027, CBDL secures a transformative partnership poised to generate multi-million-dollar revenues and accelerate nationwide expansion.
SCOTTSDALE, AZ / ACCESS Newswire / September 30, 2025 / CBD Life Sciences Inc. (OTC:CBDL), through its operating subsidiary CBD Vault, today announced a game-changing client acquisition with Smoking Scholars, a premier dispensary located at 784 Allerton Ave in the Bronx, New York. This strategic agreement, finalized following CBDL's successful showcase at the NECANN New Jersey Conference, positions the Company to capture a powerful share of the booming New York cannabis and CBD marketplace.
Smoking Scholars is a multi-million-dollar enterprise with an elite client roster stretching across the United States. Their decision to bring CBD Vault into their packed product catalog is a resounding endorsement of CBDL's premium formulations and an entry point into one of the most competitive and rewarding markets in the nation.
Under the agreement, Smoking Scholars has placed a significant initial order featuring:
CBD Pain Relief Cream
CBD Massage Oil
Full Spectrum Gummies
CBD Infused Tea
Reishi Mushroom Face Cream
This order alone has the potential to generate hundreds of thousands in revenue within the next 12 months, with repeat orders expected as consumer demand for CBD wellness products accelerates. Importantly, this is just one of many dispensaries CBDL is securing as part of its rapid nationwide expansion.
Tapping Into One of America's Fastest-Growing Markets
New York's cannabis industry is undergoing explosive growth, with annual dispensary sales projected to exceed $4.4 billion by 2027. Consumer spending in the state is surging across both recreational and wellness categories, creating unparalleled opportunities for innovative brands like CBD Vault.
"Securing a powerhouse partner like Smoking Scholars is a watershed moment for our Company," said Lisa Nelson, President & CEO of CBD Life Sciences Inc. "This agreement validates our products on a national scale and gives us a strategic foothold in one of the most high-value markets in the country. For our shareholders, this deal represents not just immediate revenue but the beginning of long-term exponential growth."
Building Momentum from NECANN
CBDL's presence at NECANN continues to pay dividends. In addition to the Smoking Scholars partnership, management is actively engaged with multiple high-profile dispensaries across the Northeast, creating a robust pipeline of potential deals. The Company anticipates announcing additional agreements in the near future, further expanding its footprint and accelerating revenues.
Positioned for Long-Term Growth
With a diverse portfolio spanning pain management, relaxation, and skincare, CBDL is uniquely positioned to meet surging consumer demand for CBD and mushroom wellness products. Analysts forecast the global CBD market to grow at a CAGR of over 31% through 2030, with U.S. demand driving much of that expansion. By aligning with large-scale dispensary partners, CBDL is executing a strategy designed to capture substantial market share and deliver maximum shareholder value.

About CBD Life Sciences Inc. (CBDL)
CBD Life Sciences Inc. is a publicly traded company (OTC:CBDL) specializing in high-quality cannabidiol (CBD) and mushroom wellness products. Through its wholly owned subsidiary CBD Vault, the Company offers a diverse range of formulations including tinctures, gummies, creams, topicals, teas, and functional mushroom blends. With a growing retail footprint and rapidly expanding wholesale partnerships, CBDL is committed to building shareholder value by capitalizing on the booming global wellness industry.
Follow our social media for the latest updates!
X: https://www.x.com/CBDL_StockOTC
Instagram: https://www.instagram.com/cbd.vault
Website: https://www.thecbdvault.com
IR Contact: [email protected]
Stay Connected & Be the First to Try Our New Functional Mushroom Products!
Mushroom Madness Instagram: https://www.instagram.com/mushroom.madnessaz
Mushroom Madness Website: https://www.mushroommadness.shop
Forward-Looking Statements
Except for the historical information contained herein, the matters discussed in this press release are forward-looking statements. Actual results may differ materially from those described in forward-looking statements and are subject to risks and uncertainties. See CBD Life Sciences, Inc's, Inc.'s filings with OTC Markets, which may identify specific factors that may cause actual results or events to differ materially from those described in the forward-looking statements.
Safe Harbor Statement
This release includes forward-looking statements, which are based on certain assumptions and reflects management's current expectations. These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results or events to differ materially from current expectations. Some of these factors include: general global economic conditions; general industry and market conditions, sector changes and growth rates; uncertainty as to whether our strategies and business plans will yield the expected benefits; increasing competition; availability and cost of capital; the ability to identify and develop and achieve commercial success; the level of expenditures necessary to maintain and improve the quality of services; changes in the economy; changes in laws and regulations, including codes and standards, intellectual property rights, and tax matters; or other matters not anticipated; our ability to secure and maintain strategic relationships and distribution agreements. The Company disclaims any intention or obligation to update or revise any forward-looking ability to secure and maintain strategic relationships and distribution agreements. The Company disclaims any intention or obligation to update or revise any forward-looking statements.
Contact Information
Lisa Nelson
CEO
[email protected]
4802091720
SOURCE: CBD Life Sciences, Inc.
View the original press release on ACCESS Newswire
Th.Berger--AMWN